ArticleClinical and experimental medicine2026
The burden and unique patterns of extraintestinal manifestations in Chinese inflammatory bowel disease: a nationwide multicenter investigation.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Extraintestinal manifestations (EIMs) are a significant disease burden in inflammatory bowel disease (IBD). However, large-scale epidemiological data from the Chinese population remain scarce. This nationwide, multicenter, retrospective cross-sectional study included 2,252 adult IBD inpatients from 10 clinical centers. Data on demographics, clinical features, and EIMs were collected and analyzed using descriptive statistics and logistic regression. Of the 2252 patients, 384 (17.1%) reported at least one EIM. Among these, data on temporal sequence were available for 310 patients, of whom 70 (22.6%) developed their first EIM before the onset of intestinal symptoms. The overall prevalence of EIMs was significantly higher in Crohn's disease (CD) than in ulcerative colitis (UC) (20.5% vs. 15.4%, P = 0.003). Joint manifestations (10.0%) and aphthous ulcers (5.5%) were most common, with aphthous ulcers significantly more frequent in CD (11.2% vs. 2.8%, P < 0.001). The prevalence of classic EIMs such as arthritis/arthralgia (8.0%), uveitis (0.5%), and erythema nodosum (0.9%) fell within the low-to-mid range of global reports. Significant co-occurrence was observed among EIMs. For example, arthritis/arthralgia showed strong associations with uveitis (OR = 31.88) and erythema nodosum (OR = 13.34). Analysis of medication history revealed higher use of infliximab in patients with arthritis/arthralgia (47.0%) and pyoderma gangrenosum (71.4%), and frequent glucocorticoid use in those with venous thromboembolism (72.4%). In this inpatient-based cohort, the lower prevalence of classic EIMs in Chinese IBD patients may reflect clinical underdetection or genuine epidemiological differences. EIMs can precede intestinal symptoms and influence each other, underscoring the need for proactive, systematic assessment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.